QUAL-IF-AI: Quality Control of Immunofluorescence Images using Artificial Intelligence

An unsupervised learning clustering workflow for automated cell phenotyping of hyperplex immunofluorescence images reveals cell types and neighbourhoods

An unsupervised learning clustering workflow for automated cell phenotyping of hyperplex immunofluorescence images reveals cell types and neighbourhoods

Adding space to TiME by sequential immunofluorescence: a new dimension for the spatial biomarkers painting in a clinical cohort of lymphoma cases

Adding space to TiME by sequential immunofluorescence: a new dimension for the spatial biomarkers painting in a clinical cohort of lymphoma cases

Integration of RNA in situ hybridization and sequential immunofluorescence for same-slide fully automated multiomics analysis of the tumor microenvironment

Integration of RNA in situ hybridization and sequential immunofluorescence for same-slide fully automated multiomics analysis of the tumor microenvironment

Cell Spotter (CSPOT): A machine-learning approach to automated cell spotting and quantification of highly multiplexed tissue images

Development and optimization of a broad hyperplex immunofuorescence assay for tumor immune microenvironment characterization

Development and optimization of a broad hyperplex immunofuorescence assay for tumor immune microenvironment characterization

Profiling Cytokeratins in the Tumor Microenvironment Using Multiplex Immunofluorescence

Profiling Cytokeratins in the Tumor Microenvironment Using Multiplex Immunofluorescence

Immune Landscape of Adenoid Cystic Carcinoma using Multiplex Immunofluorescence and Digital Pathology

Immune Landscape of Adenoid Cystic Carcinoma using Multiplex Immunofluorescence and Digital Pathology

A Modified BPaL Regimen for Tuberculosis Treatment replaces Linezolid with Inhaled Spectinamides

Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment

Optimal Antitumor Immunity is Triggered by WTX-124, a Clinical Stage Conditionally Activated INDUKINE™ Molecule that Releases Fully Potent IL-2 into the Tumor Microenvironment